首页> 外文期刊>Endocrine >BRAF~(V600E) associates with cytoplasmatic localization of p27kipl and higher cytokeratin 19 expression in papillary thyroid carcinoma
【24h】

BRAF~(V600E) associates with cytoplasmatic localization of p27kipl and higher cytokeratin 19 expression in papillary thyroid carcinoma

机译:BRAF~(V600E) associates with cytoplasmatic localization of p27kipl and higher cytokeratin 19 expression in papillary thyroid carcinoma

获取原文
获取原文并翻译 | 示例
           

摘要

The genetic alterations are responsible for the altered protein expression in tumors. The knowledge of the link between the altered protein expression and genetic alterations may provide potentially important biological and clinical information. In this study, the expression of some protein markers (Gal-3, p21Kipl, CK19) known to be associated to the papillary thyroid carcinoma (PTC) was assessed in a series of surgical samples by immunohisto-chemistry, and the association between expression of these markers and the BRAF~(V600E) mutation was investigated. Gal-3 positive staining was evident in 26 of benign nodules. The BRAF~(V600E) mutation and Gal-3 expression, were found in 55.5 and 87 of PTC respectively, and were unlinked. The expression of CK19 in benign nodules was weak and limited to scattered follicular cells. Diffuse cytoplasmatic expression of CK19 was present in malignant tumors in a variable percentage of cells. A higher percentage of CK19 expressing cells was associated with BRAF~(V600E) (P 15 of cells with nuclear staining were 72 (66.7 ), 24 (22.2 ), and 12 (11.1 ) respectively. In BRAF~(V600E) positive tumors, the cytoplasmatic localization of p27kipl was significantly more frequent (P = 0.024). In conclusion, we provide evidences that BRAF~(V600E) is non-associated with Gal-3 expression, whereas it is associated with cytoplasmatic localization of p27kipl and higher CK19 expression in PTC.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号